Objective: Protamine has been shown to have an inhibitory effect on protein lipase in vitro; the objective of this study was to evaluate the antiobesity activity effect of protamine in obese induced rats, and to evaluate the effect of protamine on postprandial hypertriacylglyceridemia in rats by intragastric administration of a lipid emulsion containing corn oil. Design: Two experiments were carried out: (1) In a parallel study in rats, we administered a lipid emulsion containing corn oil plus 0, 200 or 500 mg kg -1 of protamine intragastrically. (2) In a randomized parallel prospective rats experiment, rats were fed with a high-fat diet and 0, 200 or 500 mg of protamine per kg of animal weight during 5 weeks. Subjects: Male Sprague-Dawley rats. Measurements: In experiment 1, plasma triacylglycerol levels after oral administration of lipid emulsion were determined. In experiment 2, weight gain, concentrations of plasma triacylglycerol, plasma total cholesterol and albumin were determined, and the subcutaneous and visceral adipose tissues were weighed. Results: Plasma triacylglycerol concentration in rats administered with 200 or 500 mg kg -1 of protamine was significantly lower than that in rats in the control group (200 mg kg -1 of protamine, Po0.05 at 1, 2, 3 and 4 h; 500 mg kg -1 of protamine Po0.05 at 2, 3 and 4 h). In rats fed with a high-fat diet, and 200 and 500 mg kg -1 of protamine, there was a decreased body weight gain by 52 and 66 g, respectively, reduced visceral fat by 5 and 8 g, respectively and subcutaneous tissue weights by 12 and 15 g, respectively. Plasma triacylglycerol was 17 and 45 mg per 100 ml lower in rats fed with high-fat diet plus 200 and 500 mg kg -1 of protamine, respectively. And cholesterol concentrations were 18 and 22 mg per 100 ml lower in both protamine groups, respectively. Conclusion: Our study demonstrates that protamine reduce weight gain and body fat accumulation through the inhibition of dietary fat absorption.
Introduction
Obesity is a recognized a health problem that has reached epidemic proportions. More than 1 billion adults in the world are overweight, and at least 300 million from them are clinically obese. 1 Obesity is associated with the development of type 2 diabetes, coronary hearth disease and increased incidence of other diseases, such as certain forms of cancer and respiratory complications. 2 The most common strategies to combat obesity involves the use of relative low-fat diets combined with increased physical activity and the use of certain agents that suppress food intake, increase thermogenesis, suppress fat absorption or inhibit adipocyte differentiation. 3, 4 Anoretic agents, such as sibutramine and the combination of phentermine-fenfluramine are widely used around the world; however, they are associated with serious side effects, including increased blood pressure and effects in the central nervous system. 5 Inhibition of the digestion of dietary lipids is a reasonable target for pharmacological intervention because it does not involve a mechanism of action over a central nervous system reducing side effects. Inhibiting fat absorption is achieved by the inhibition of pancreatic lipase, a key enzyme for lipid breakdown that leads to the absorption of fatty acids. Many lipase inhibitors are widely distributed in nature. The use of orlistat (tetrahydrolipstatin) has been clinically proved to be effective to suppress body weight gain. 6, 7 Han et al. 8 , showed that an aqueous extract of Platycodi radix inhibited the hydrolysis of triolein emulsified with phosphatidylcholine by pancreatic lipase in vitro, and they argued that this inhibitory effect may be attributed to the saponins present in the aqueous extract. Yoshikawa et al. 9 isolated phenolic compounds with lipase inhibitory and lipolytic activities from the roots of Salacia reticulate. It is known that proteins and peptides inhibit hydrolysis of triglycerides emulsions by pancreatic lipase. Satouchi et al. 10 isolated a lipase-inhibiting protein from lipoxygenasedeficient soybean seeds. Tani et al.
11 purified and characterized a proteinous inhibitor of lipase from wheat flour with molecular masses of 28 and 25 kDa. The amino acid sequences from the N-termini of the inhibitors were predominantly composed of basic amino acids. Tsujita et al. 12 showed that basic proteins such as protamine strongly inhibited hydrolysis of triolein emulsified with soybean phosphatidylcholine by pancreatic and carboxylester lipase. Protamine is a basic protein, which is generally obtained from fish and consist of a group of heterogeneous peptides with an average molecular weight of 4500 Da. Approximately 67% of the amino acid composition in protamine is arginine. 13 Kinetics studies have shown that the inhibition of pancreatic lipase by basic proteins is related to their ability to interact with the emulsified substrate and to hinder the absorption of the enzyme to the interface, 14 suggesting that basic proteins are good candidates as agents that inhibit lipid absorption; however, in vivo experiments have not been reported. The purpose of this study was to investigate the effect of the basic peptide protamine on weight gain and fat absorption in rats. The application of protamine and another peptide in obesity treatment has been disclaimed for the privilege of the invention of the National Phase of PCT under serial no. MX2005/000058. 15 
Methods

Study design
The study was divided in two experiments, one studied the effect of protamine intake in fat absorption and a second experiment to determine the effect of protamine intake on body fat accumulation and body weight gain.
The assessment of fat absorption was achieved by measuring plasma triacylglycerol (TG) levels after oral administration of lipid emulsion to rats. A total of 32 male SpragueDawley rats were fasted overnight and were randomly divided into four groups. Each group received 1.5 ml of lipid emulsion and 0, 50, 200 or 500 mg kg -1 of protamine, respectively. Both the lipid solution and protamine earlier dissolved in distilled water were administered intragastrically using a bulbed needle. Blood samples were taken from the tail vein at 0, 0.5, 1, 2, 3, 4 and 6 h after the administration of the lipid emulsion and protamine solution using a heparinized capillary tube, and centrifuged at 3500 g for 5 min in a model M-25 Solvat centrifuge (México City, México) to obtain the plasma. The plasma TG concentration was determined using a TG test kit (Bayer , Sées, France).
To examine the effect of protamine in weight gain, 30 male Sprague-Dawley rats of 7 weeks old were randomly assigned to one of the three groups, each group matched for body weight, after 12 days of being fed with diet containing 18% protein ad libitum. The two tests groups received doses of 200 mg (group 1) or 500 mg of protamine (group 2) per kg of animal (n ¼ 10 in each group at any time). Protamine solution was orally administered with a bulbed needle once a day for 5 weeks. Doses of 200 and 500 mg kg -1 of protamine were selected according to the results of the first experiment that measured the effect of protamine on plasma TG levels after oral administration of lipid emulsion. A dose of 50 mg kg -1 of protamine was discarded as it did not produce a significant effect on lipid absorption. A third group of rats was a control to which the same volume of distilled water was administered instead of protamine solution. All groups received a high-fat diet containing 40% beef tallow, 30% casein, 10% corn starch, 10% sugar, 5% cellulose, 1% vitamin mixture, 3.5% mineral mixture, 0.2% coline and 0.3% methionine. Body weight was measured every other day (three times a week) for 5 weeks. Food intake in each group was also evaluated by monitoring daily all food consumed by each rat and the values were converted to calorie intake (kJ per day per rat). After 5 weeks of consuming the experimental diet, fasting blood samples of each rat were taken from the heart by venous punction under anesthesia with zoletil of 0.5 mg kg -1 . After the sample was taken, rats were killed with an overdose of zoletil. Plasma from each sample was separated by centrifugation and frozen at À801C until analysis. Plasma TG concentration, plasma total cholesterol (TC) and albumin were determined as described below.
The subcutaneous and visceral adipose tissues were quickly removed and weighed. To make sure that all the fat was removed, a tissue section slide was stained following the Oil Red Staining procedure using a tissue containing fat as a positive control tissue. 16 
Biochemical analysis
The activity of serum alanine aminotransferase (ALT), as well as the concentrations of TG and TC, was determined using the corresponding commercial test kit (Bayer). Each assay is a colorimetric assay with the detection of highly colored end ) and colic acid (1 g l -1 ).
Animals
Male Sprague-Dawley rats, 7 weeks old and weighing B200 g, were purchased from Harlan de México, and housed for 12-20 days before the start of the experiment at a controlled temperature (21-231C) with a 12 h/12 h lightdark cycle. The animals were given free access to food and water. After the adaptation, healthy animals were used in these experiments. All animal experiments were carried out following the governmental regulations for ethical use of animals in research protocols (Norma Oficial Mexicana NOM-062-ZOO-1999, Technical specifications for production, care and use of laboratory animals). The experimental protocol was approved by the Animal Studies Committee of the University of Querétaro.
Statistical analysis
Values of all parameters were expressed as the mean ± s.d. of the mean of 8 or 10 animals for experiments 1 and 2, respectively. Differences in mean values between groups were analyzed by one-way analysis of variance followed by Duncan's multiple range test. A P-value of o0.05 was considered statistically significant.
We certify that all applicable institutional and governmental regulations concerning the ethical use of animals were followed during this research.
Results
Effect of protamine on fat absorption Figure 1 shows the serial changes in plasma TG concentration when lipid emulsion with or without protamine was administered orally to rats. On an average, basal level of plasma TG concentration in all groups was around 50 mg per 100 ml. Intragastric administration of lipid emulsion to rats significantly increased plasma TG concentration at 1-4 h after the fat administration (Po0.05), reaching a maximum level of about 120 mg per 100 ml after 4 h following by a gradual decrease until reaching a concentration similar to baseline after 6 h in the group of rats without protamine (control group). The plasma TG concentration in rats administered with fat emulsion plus 200 mg kg -1 of protamine was significantly lower at 2 and 3 h after administration than those in rats administered with fat emulsion alone. Oral administration of fat emulsion plus 500 mg kg -1 of protamine also produced lower TG concentrations compared with the administration of fat emulsion alone at 2, 3, and 4 h after administration. Maximum plasma TG concentration was 75 ± 10 mg per 100 ml for the group receiving 200 mg kg -1 of protamine, and 85±12 mg per 100 ml for the group receiving dose of 500 mg kg -1 of protamine. No significant differences were found between rats treated with 200 and 500 mg kg -1 of protamine. No differences were observed between control group and rats treated with 50 mg kg -1 of protamine at any time. Plasma cholesterol was not affected by any protamine dose at any time after oral administration (data not shown).
Effect of protamine on weight gain
There was not significant difference in mean energy consumption between the group receiving the high-fat diet and any high-fat plus protamine groups. The mean food energy consumption per week per rat was 2131±147 kJ in the high-fat diet group, 2079 ± 105 kJ in the high-fat plus 200 mg kg -1 protamine group and 1872 ± 126 kJ in the highfat plus 500 mg kg -1 protamine group. Effect of protamine in obesity MÁ Duarte-Vázquez et al compared with the high-fat diet group after 5 weeks, whereas the addition of 500 mg kg -1 of protamine produce a significantly reduction of 30% (Po0.05) in weight gain during the same treatment period. The difference in body weight gain among groups started to be significant after 9 days of intervention.
The effect of different doses of protamine on the accumulation of visceral and subcutaneous adipose tissue in rats fed a high-fat diet for 5 weeks is shown in Table 1 . The amounts of both visceral and subcutaneous adipose tissue of the experimental groups fed with high-fat diet plus 200 and 500 mg kg -1 of protamine were significantly lower (Po0.05) than that of the group fed with the high-fat diet alone. No differences were observed between both the groups receiving protamine. Fasting plasma TG and TC concentrations caused by the high-fat diet were significantly decreased (Po0.05) by the addition of 200 or 500 mg kg -1 of protamine (Table 2 ).
Protamine treatment with 200 or 500 mg kg -1 dose caused 17
and 35% decrease in serum TG concentration, compared with the high-fat diet, respectively. The difference between 200 and 500 mg kg -1 was also significant (Po0.05). TC levels were also affected by protamine treatment as dose of 200 or 500 mg kg -1 of protamine produced 18 and 23% decrease, respectively, compared with the high-fat diet (Po0.05). For TC no significant differences between both the protamine groups were observed. We also measured plasma albumin as indicative of depletion of nutrients. No significant changes were observed among groups. Also the activity of serum ALT was unaffected by protamine administration.
Discussion
Lipase is a key enzyme of dietary TG digestion and assimilation. It acts at the surface of the emulsified lipid droplets; in contrast to their substrates, lipases are watersoluble proteins. For catalysis, these enzymes must be absorbed or penetrate to the lipid surface; therefore, any compound that alters the equilibrium of the emulsion may reduce lipase activity. Many studies have shown that some proteinous-like compound can inhibit lipase activity, 12, 17, 18 and it has been suggested that the inactivation of lipase by proteinous compounds is caused not by the direct interaction between enzyme and inhibitor but by the interaction between the inhibitor and the emulsified substrate. Protamine is a basic peptide isolated mainly from salmon that have shown lipase inhibitory activity in substrates containing phosphatidylcholine. 12 This result suggests that protamine is a strong candidate among agents that inhibit lipid absorption and therefore it is possible that protamine may prevent high-fat diet-induced obesity through inhibition of pancreatic lipase activity. To test this possibility, we first evaluated the effect of protamine on plasma TG concentration after oral administration of a lipid emulsion containing corn oil to rats, and we found that protamine reduced the elevation on plasma TG levels after oral administration of a lipid emulsion. After fat digestion, pancreatic lipase present in pancreatic juice catalyzes the hydrolysis of emulsified esters of glycerol and long-chain fatty acids. Short-chain fatty acids can be directly absorbed into the blood, whereas long-chain fatty acids and monoacylglycerol combine with bile salts to form water-soluble micelles. 19 The micelles are absorbed into the mucosal cells of the intestine, and the fatty acids and monoacylglycerol are resynthesized into TG. These TG molecules are formed into small particles known as chylomicrons, which consist of Table 1 Effect of protamine on the body weight gain and body fat in rats feed a high-fat diet for 5 weeks Effect of protamine in obesity MÁ Duarte-Vázquez et al TG, the sterol lipid cholesterol and apoproteins. These chylomicrons are transported to the muscle and adipose tissue by the blood stream. Thus, the increase in plasma TG is caused by an elevation of chylomicron TG. A compound that suppresses postprandial hipertriacylglyceridemia is thought to act by at least two different mechanisms, that is, inhibition of absorption of fat from the intestine and promotion of catabolism of TG present in bloodstream as chylomicrons. The hypotriacylglyceridemic activity of protamine is likely because of the former mechanism, as protamine strongly inhibits pancreatic lipase in vitro. 12 The result of our study suggests that the basic protein protamine might exert antiobesity and antihyperlipidemic actions, mediated though suppressing the intestinal absorption of dietary fat by inhibiting lipase enzyme. Reducing fat absorption is an effective way to suppress body weight gain, as seen in the clinical use of orlistat (tetrahydrolipstatin), 6 a specific lipase inhibitor. In this study we found that the administration of protamine significantly suppressed the increase in body weight in rats fed with a high-fat diet. This suppression on body weight did not depend on decreased food or energy intake, as no significant differences were observed in food intake among the different treatment groups in this study. The treatment with protamine also significantly reduced the final visceral and adipose tissue weight as compared with that of high-fat diet group with no protamine, indicating that protamine may reduce fat accumulation in the subcutaneous and visceral adipose tissue induced by high-fat diet. This was consistent with the reduced body weight gain of groups receiving protamine. The effect of protamine in the reduction of visceral adipose tissue weight is of special relevance, as it has been observed that the accumulation of visceral fat is the main risk factor for the development of chronic degenerative illnesses as the type 2 diabetes due to glucose intolerance and hyperinsulinaemia resulting from insulin resistance. 20 The administration of 200 and 500 mg kg -1 of protamine for 5 weeks caused significant changes in fasting blood lipid concentrations. The concentrations of serum TG and TC were decreased significantly, whereas the levels of highdensity lipoprotein were almost unchanged. This suggests that the cholesterol lowering effect of protamine was due to the reduction of low-density or very-low-density cholesterol.
The changes in the blood parameters of rats fed with a diet containing protamine indicated an improvement in the atherogenic index. Feeding high-fat diet elevated plasma TG and TC in our study. Some studies have shown that the non-absorptive polybasic antibiotic neomycin in vitro induced the precipitation of mixed micelle solution, and in vivo reduced the plasma lipids in type II hyperlipoproteinemia. 21, 22 As protamine is a polybasic peptide, we suggest that its lowering lipid effect might be because of the same mechanism as neomycin.
Protamine administration did not change the activity of serum ALT. This enzyme is a sensitive indicator of active liver damage; an increased serum ALT activity indicates recent or ongoing liver cell damage. An increase of at least three times the normal concentration indicates significant liver damage within the earlier 2-5 days. Our results suggest that protamine did not produce liver damage.
Protamine may prevent the induced increases in body weight and also in subcutaneous and visceral adipose tissue weight because of the high-fat diet by inhibiting intestinal absorption of dietary fat through the inhibition of lipase activity. Inhibition of dietary fat absorption by using protamine may also prevent increases in plasma TG and TC.
A possible downside that may be expected with the use of protamine in humans is related with its mechanism. The inhibition of lipase produced by protamine may vary according to the substrate emulsifier; as the emulsification environment is less constant in humans than in rats, the effect of protamine might be variable. Owing to its polypeptide nature, protamine might be partially degraded by human peptidases affecting its activity. Therefore, further experiments are needed to confirm the effectiveness of protamine in human obesity. Effect of protamine in obesity MÁ Duarte-Vázquez et al
